Clinical Trial

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-12-18; most recent amendment 2024-08-06.
Status change: Enrolling by Invitation → Recruiting 2024-08-06
Status change: Recruiting → Enrolling by Invitation 2023-04-14
Status change: Active, Not Recruiting → Recruiting 2021-03-02
Status change: Recruiting → Active, Not Recruiting 2020-04-15
Status change: Not Yet Recruiting → Recruiting 2019-04-08
Trial Details
NCT Number NCT03781752
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Florida, Children's Hospital Medical Center, Cincinnati, Seattle Children's Hospital
Conditions ADHD, Attention Deficit Hyperactivity Disorder
Enrollment 500 participants
Start Date 2018-03-04
Primary Completion 2025-08 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2024-08-09